{"links":{"html":"https://www.erudio.com/reports/g-hope-001-nct06238843","json":"https://www.erudio.com/reports/g-hope-001-nct06238843.json","markdown":"https://www.erudio.com/reports/g-hope-001-nct06238843.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"g-hope-001-06238843"}},"request":"https://www.erudio.com/contact?report=g-hope-001-06238843"},"offer":{"cited_commentary_sources":32,"verified_hcp_statements":83,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":11,"optional":true,"price_per_verified_person_usd":15,"price_usd":165,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"g-hope-001-nct06238843"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=g-hope-001-06238843","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/g-hope-001-nct06238843","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-27T22:33:43.896659Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":21,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":20,"title":"Primary endpoint: progression free survival(PFS)"},{"claim_count":20,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":17,"title":"Primary endpoint: overall survival(OS)"},{"claim_count":11,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":11,"title":"Secondary endpoints"},{"claim_count":13,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":12,"title":"Population and setting"},{"claim_count":13,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":13,"title":"The comparison"},{"claim_count":18,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.interventions","source_count":13,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":8,"title":"Design and conduct"},{"claim_count":9,"coverage":"discussed","id":"A1","source_count":1,"title":"Specimen heterogeneity, discordance and borderline eligibility"},{"claim_count":7,"coverage":"discussed","id":"A2","source_count":4,"title":"Prior zolbetuximab and conditional rebiopsy before an ADC"},{"claim_count":11,"coverage":"discussed","id":"A3","source_count":1,"title":"Assay alignment, reporting and testing-service readiness"},{"claim_count":11,"coverage":"discussed","id":"A4","source_count":6,"title":"Cross-program interpretation, payloads and Fc-design hypotheses"},{"claim_count":7,"coverage":"discussed","id":"A5","source_count":6,"title":"Geographic applicability and the threshold for a global-standard judgment"},{"claim_count":12,"coverage":"discussed","id":"A6","source_count":9,"title":"Development interest, earlier evidence and future combinations"},{"claim_count":7,"coverage":"discussed","id":"A7","source_count":7,"title":"Regulatory milestones and prospective access"}],"counts":{"cited_sources":32,"claims_by_expression_type":{"comparison":6,"experience":2,"interpretation":16,"opinion":18,"primary_context":1,"question":6,"restatement":20,"uncertainty":3,"unspecified":11},"claims_by_kind":{"protocol_statement":1,"source_observation":82},"clinician_statements":4,"evidence_units":59,"findings":9,"organisational_accounts":8,"people_cited":16,"people_identity_verified":11,"people_total":16,"screened_sources":51,"verified_claims":83},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":1,"views":1},"has_counterview":false,"limitations":2,"links":{"context":2,"support":7},"ma_question":true,"named_voices":3,"passages":4,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Post-zolbetuximab activity and geographic applicability limit the adoption conclusions drawn"},{"id":"F2","structure":{"claims":21,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":13,"views":6},"has_counterview":false,"limitations":3,"links":{"context":3,"support":22},"ma_question":true,"named_voices":15,"passages":19,"sources":19,"sources_by_kind":{"commentary":16,"media":3}},"title":"Favorable efficacy reactions refer to different interim accounts, not one interchangeable result set"},{"id":"F3","structure":{"claims":17,"claims_by_group":{"comparisons":3,"experience":0,"questions":1,"restated":5,"views":8},"has_counterview":true,"limitations":4,"links":{"context":2,"support":19},"ma_question":true,"named_voices":11,"passages":15,"sources":12,"sources_by_kind":{"commentary":11,"media":1}},"title":"A possible gastrointestinal tolerability advantage is welcomed, but remains conditional"},{"id":"F4","structure":{"claims":11,"claims_by_group":{"comparisons":3,"experience":0,"questions":1,"restated":2,"views":5},"has_counterview":false,"limitations":3,"links":{"context":2,"support":12},"ma_question":true,"named_voices":6,"passages":9,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Expression thresholds and ADC design make cross-program rankings unsafe"},{"id":"F5","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":2,"views":4},"has_counterview":false,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":2,"passages":7,"sources":1,"sources_by_kind":{"media":1}},"title":"Borderline and discordant results prompt investigation, not averaging or rounding into eligibility"},{"id":"F6","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":3},"ma_question":true,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"media":1}},"title":"Retesting is advocated, but its urgency depends on prior treatment and feasibility"},{"id":"F7","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":1,"views":7},"has_counterview":false,"limitations":2,"links":{"context":0,"support":13},"ma_question":true,"named_voices":2,"passages":10,"sources":1,"sources_by_kind":{"media":1}},"title":"Testing capacity, report detail and oncology–pathology dialogue are practical readiness requirements"},{"id":"F8","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":3,"views":5},"has_counterview":false,"limitations":2,"links":{"context":0,"support":11},"ma_question":true,"named_voices":8,"passages":9,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"Development enthusiasm extends to combinations, without establishing combination benefit"},{"id":"F9","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":7,"views":1},"has_counterview":false,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":5,"passages":8,"sources":8,"sources_by_kind":{"commentary":6,"media":2}},"title":"Regulatory progress is discussed as prospective access, not current availability everywhere"}],"medical_affairs_question":"What evidence, patient-selection information and testing conditions are needed to translate the favorable signal into an appropriate later-line option, especially after zolbetuximab and outside the studied Asian population?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Strong enthusiasm does not settle post-zolbetuximab use or global applicability"},{"id":"section-2","level":2,"title":"Positive efficacy reactions require analysis-specific interpretation"},{"id":"section-3","level":2,"title":"Gastrointestinal differentiation is anticipated, not proven head to head"},{"id":"section-4","level":2,"title":"Biomarker selection and ADC design complicate comparisons"},{"id":"section-5","level":2,"title":"Sampling uncertainty does not justify changing a negative result"},{"id":"section-6","level":2,"title":"Rebiopsy advocacy includes selective exceptions"},{"id":"section-7","level":2,"title":"Service readiness goes beyond a binary biomarker result"},{"id":"section-8","level":2,"title":"Research enthusiasm remains distinct from a combination recommendation"},{"id":"section-9","level":2,"title":"Regulatory milestones should not be read as universal access"},{"id":"section-10","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":17},{"id":"F3","shared_claims":9},{"id":"F8","shared_claims":2}],"id":"T1","label":"Primary endpoint: progression free survival(PFS)"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":14},{"id":"F3","shared_claims":6},{"id":"F8","shared_claims":2}],"id":"T2","label":"Primary endpoint: overall survival(OS)"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":9},{"id":"F3","shared_claims":6}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":11},{"id":"F3","shared_claims":5},{"id":"F8","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":13},{"id":"F3","shared_claims":8},{"id":"F8","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":8},{"id":"F3","shared_claims":17},{"id":"F4","shared_claims":3}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":4},{"id":"F8","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-27T22:33:43.896659Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-27T22:51:52Z","record_hash":"0247b45d2aefd853fab1f637e7baccd20c689d9eecc8257097b80556dbef00f3","release_hash":"ca3829e05e5a9ab9dfc9c8e7bccf07e239a0703508877592e0ead1d97829453a","report_id":"erudio-nct06238843","run_id":"2fd48449-ee1b-4dbe-bfde-0063f7785fb7","schema_version":"5.0","slug":"g-hope-001-06238843","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on G-HOPE-001 in the sources reviewed for this edition leads to one open question: What evidence, patient-selection information and testing conditions are needed to translate the favorable signal into an appropriate later-line option, especially after zolbetuximab and outside the studied Asian population? Its leading findings: (1) post-zolbetuximab activity and geographic applicability limit the adoption conclusions drawn. (2) favorable efficacy reactions refer to different interim accounts, not one interchangeable result set. (3) A possible gastrointestinal tolerability advantage is welcomed, but remains conditional. 6 more findings follow. 32 of 51 screened sources are cited; not all HCPs or all public discussion.","meta_description":"51 sources screened · 83 verified statements (4 from speakers with a confirmed clinical role) from 32 sources · 9 findings. Updated Oct 27, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-27T22:51:52Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-27T00:00:00Z","summary":"A summary sentence now uses the wording of the finding it summarizes."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":51},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 matching source (1 X thread) could not be read and is not included.","Not yet captured in this edition: a view on later-line efficacy of a claudin-targeted antibody–drug conjugate versus standard treatment in advanced gastroesophageal adenocarcinoma.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","61 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not represent all HCPs or all public discussion. Some potentially relevant discussion could not be read or fully assessed, and unnamed or differently transcribed references may be missing.","No full protocol or exact-trial results publication was available. Registry material describes planned methods and does not independently validate numerical findings shared in commentary.","Enrolment figures, interim-analysis labels and some outcomes differ across posts. These differences are preserved rather than reconciled without supporting information.","Prior zolbetuximab exposure was described as unreported in a release. This does not establish that exposure was absent or determine efficacy after that treatment.","The material includes individual opinions, organization and news accounts, and relayed findings. Source totals and reposts must not be interpreted as independent clinician counts or consensus.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Gastrointestinal safety differentiation, Fc-design explanations and expression requirements include expectations and hypotheses, not demonstrated head-to-head advantages. Different severe-adverse-event definitions are not interchangeable.","Regulatory statements are time-specific reports. Independently confirmed current product-label and local-access information was unavailable."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":28,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":32},"count":32,"evidence_window":{"end":"2026-10-26","start":"2024-05-07"},"retrieval_snapshot":"2026-10-27T00:54:46.958097Z","timeline":[{"count":1,"week":"2024-W19"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2025-W29"},{"count":2,"week":"2026-W23"},{"count":2,"week":"2026-W40"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":20,"week":"2026-W43"},{"count":3,"week":"2026-W44"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06238843:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06238843:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7sx4xfvdi6ayikr76lbjpn4p-3mxdjhdfer22j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3myk3tqa2kn2u","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-peqso3z43zumyccd2g6s3u22-3mykf7ces6k25","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3myhfs6b3dr2k","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:0fd78a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1787793471505412518:b34d423e-c5bf-4337-9b49-28aff777e6e0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1806954505721753649:9f4b7482-f307-4530-816f-12362cc4f2ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1945331743558656304:e1af939c-2e88-452e-af4f-e92ebc8026ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062497457863528577:743d4e9a-1b23-4607-a98a-e7c1be367534","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062648224431927739:4deb0768-86bd-4346-88b7-9e9c630db7c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062849663229940031:01417ed4-509e-4afd-b8cc-68391ceaf839","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2081627523859820793:cbf49438-3cba-4ff1-adcf-339872d26c14","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102432534395306414:2bfa35cd-db10-4521-9e9f-8e5ab3a8f038","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104356268454686951:b359d6e5-399d-40a5-8f52-05cb4f96eb63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104576990355292208:37aa925b-12a5-455b-bd26-709c80675c22","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105990928217334044:c005e9b7-687f-4ccb-8337-1162e1a8d6a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110607787776745536:d02580f1-82d4-40a3-b92b-82849085c040","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111079668140900657:91592967-290a-4e8e-986a-89a2de641f0a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112885260211908948:af00f968-01ba-4431-a43c-f6356c2ba881","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112902368220287215:f730ae81-aa09-487b-9d1c-337436f579c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113094665742455043:5e30b21b-9fe5-417a-8465-e2f5c6b87a42","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113208955425984822:d6849bc3-a98e-4a9a-9b10-335399bba83b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113280507975008719:28f4bb3e-b595-42de-b245-43104ad08e6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113313616455958933:46156bf8-6aa7-4aec-9d09-556399e010b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113421387964768412:d7fcb5cf-4afc-4b97-89db-0a8207b811a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113457253718348079:1fa2d2cd-6993-4579-bb2e-18cdd0786df9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113463186456187295:d946bf23-174e-4639-98f8-f48dd0357bf1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113574199591604498:3ec79ce3-7b79-4730-84d8-a2b6a9d3051b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113586733103399411:d3a5f95b-c064-4f45-b6f7-f64b674a87f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113593924006646141:9286447f-cca0-4453-833e-ea0d657d3af4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113596197877195234:15eb16cc-ce27-438c-9b37-0d4528f8de7a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113596919117390088:1a38aa2d-7220-41b8-a1e8-754cb3d63a26","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113597180359401538:9a7d41e1-384a-47c8-b706-5b6b13a7fbb1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113600787007836508:e1803e10-a1a5-4bd0-b4b5-a37df5d8d820","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113602442881544648:44675609-ddd1-484b-97b9-da1f92af2d1f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113603906521698329:03240552-5a2f-4c8d-adbd-edaff75154c9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113608879221436902:d0de09e3-78f4-4068-87d5-801f60d7c08b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113653753043636514:ea1677bd-76f5-4ee5-aaaf-323a4c217b74","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113658057443983427:d4680c7e-bb75-4c31-8e28-2fd5205fd34c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113659128639861099:86013a51-623a-433c-ad12-7866c50c01cc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113707684537233438:cf5104f6-6a38-4c24-ad31-ab70e7492f11","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114048921022714028:d3065b82-e1fb-4cb0-a0d4-c53721e0e9f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114399299857797127:b4f5d3ea-06ab-497e-a757-cefeb375b3df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114399491256107201:24743ad0-bffb-492a-8a9b-8a3e8ee07386","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114399498529038493:3f5a0688-d87c-446c-a151-d365ce3e741c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114431819701706984:b0464c8c-e13c-44b3-ab65-b33f203fa37f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114485029770281433:19fc2586-d525-4cfd-8182-647f4b1d7e0b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114729097901355181:cc6d18d1-d867-4b5b-a420-f2e333864cda","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114788237151474172:bd2b7d55-0214-4cb1-8acd-bf5245e33f01","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:DaM2hvDBEuU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:lNX3SAdB05o","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":4,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":44,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":51},"count":51,"evidence_window":{"end":"2026-10-26","start":"2024-05-07"},"retrieval_snapshot":"2026-10-27T00:54:46.958097Z","timeline":[{"count":1,"week":"2024-W19"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2025-W29"},{"count":3,"week":"2026-W23"},{"count":1,"week":"2026-W31"},{"count":2,"week":"2026-W39"},{"count":3,"week":"2026-W40"},{"count":2,"week":"2026-W41"},{"count":2,"week":"2026-W42"},{"count":33,"week":"2026-W43"},{"count":3,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: irinotecan or paclitaxel or trifluridine/tipiracil（ ftd/tpi）","status":"unmapped"},{"reason":"Unmapped registry intervention: ibi343","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"G-HOPE-001","aliases":["G-HOPE-001","A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)","A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma"],"brief_title":"A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma"],"enrollment":{"count":464,"type":"ACTUAL"},"interventions":[{"name":"Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"IBI343","synonyms":["Arcotatug Tavatecan"],"type":"DRUG"}],"nct_id":"NCT06238843","official_title":"A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"primary_endpoints":[{"description":"Progression-free survival (PFS) is defined as the time from random assignment in the trial to disease progression or death from any cause.","measure":"progression free survival(PFS)","timeFrame":"within approximately 20 months"},{"description":"Overall survival (OS) is defined as the time from randomization to death from any cause.","measure":"overall survival(OS)","timeFrame":"within approximately 26 months"}],"registry_last_updated":"2026-05-13","registry_url":"https://clinicaltrials.gov/study/NCT06238843","short_name":"G-HOPE-001","short_name_basis":"registry_acronym","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","start_date":{"date":"2024-06-30","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"CIBI343A301","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}